Conversely, in NCI-H28 cells, treatment with CAPS 250 μM only resulted in delayed AKT and ERK1/2 activation, suggesting that additional pathways targeted by CAPS can contribute to sustaining proliferation and motility of NCI-H28 MM cells. Here, MAPK3 is linked to Miyoshi myopathy.